Gefitinib Provides Similar Effectiveness and Improved Safety Than Erlotinib for East Asian Populations with Advanced Non–small Cell Lung Cancer: a Meta-Analysis

Wenxiong Zhang,Yiping Wei,Dongliang Yu,Jianjun Xu,Jinhua Peng
DOI: https://doi.org/10.1186/s12885-018-4685-y
IF: 4.638
2018-01-01
BMC Cancer
Abstract:The first-generation epidermal growth factor receptor tyrosine kinase inhibitors gefitinib and erlotinib have both been proven effective for treating advanced non–small cell lung cancer (NSCLC), especially in East Asian patients. We conducted this meta-analysis to compare their efficacy and safety in treating advanced NSCLC in this population.
What problem does this paper attempt to address?